Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.140.1%
QQQ
716.510.03%
BTC/USD
78500.000.2789%
DIA
524.880.15%
GLD
402.810.13%
TLT
81.680.06%

Compass Therapeutics Inc

CMPXNASDAQ
Trade with Public
Trade with Public
$2.18
-0.03-1.36%
At close: Sep 9, 5:00 PM EST
$2.20
0.02010.92%
After Hours: 7:53 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Compass Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compass Therapeutics (CMPX).

Price Target Range — 11 Quarters

Analyst Consensus — 14 Analysts

1S.Buy
13Buy
Consensus RatingBuy# Analysts14Avg. Consensus PT$11Upside to Avg. PT+406.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026Piper SandlerBiren AminPT RaiseOverweight$4→$6
Apr 28, 2026Canaccord GenuityJohn NewmanPT CutBuy$13→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6

Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7

Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target

Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 price target.
Benzinga Newsdesk

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.
Vandana Singh

PRO
Guggenheim Reiterates Buy on Compass Therapeutics, Maintains $12 Price Target

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved